Gilead Sciences completed the acquisition of MYR from High-Tech Gruenderfonds Management and Maxwell Biotech Venture Fund for c. $1.8bn.

Gilead Sciences, a research-based biopharmaceutical company, completed the acquisition of MYR, a German biotechnology company, from High-Tech Gruenderfonds Management and Maxwell Biotech Venture Fund for c. $1.8bn. “We are proud of our achievement in bringing Hepcludex from preclinical stage to patients in need within such a short timeframe. We are excited to join Gilead, whose experience in the hepatitis field and global infrastructure will realize the full potential of Hepcludex and provide access to as many patients as possible around the world with this debilitating disease,” Dmitry Popov, MYR Chief Executive Officer.